RiverVest Venture Partners closes on $275 million Fund V

This can only be good news for early stage life science companies.

RiverVest Venture Partners has announced the closing of its Fund V with $275 million of capital commitments in an oversubscribed fundraise. This brings the St. Louis-based firm’s total assets under management to more than $1.6 billion.

RiverVest invests in early stage biopharma and medical device companies addressing significant unmet medical needs and has delivered consistently strong results to investors. Fund V is the firm’s largest fund to date, reflecting commitments from a wide range of institutional investors, as well as family offices and individual investors.

To learn more, click here.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to Include the name and contact information (phone and email) for follow-up.